Immunotherapies Could Play Role in CALR-Positive Myeloproliferative Neoplasms
This video highlights a study that establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.
In this video, Cansu Cimen Bozkus, PhD, of the Icahn School of Medicine at Mount Sinai in New York, discusses a study that showed that somatic mutations in the calreticulin (CALR) gene can induce T cell responses in patients with myeloproliferative neoplasms. The study establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.
Bozkus presented results of the study (abstract 384) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
